Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price reached a new 52-week high on Monday . The company traded as high as $35.19 and last traded at $32.11, with a volume of 947989 shares traded. The stock had previously closed at $27.49.
Analyst Ratings Changes
MTSR has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company. Guggenheim increased their target price on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday. Bank of America assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective for the company. Finally, Evercore ISI assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company.
Get Our Latest Research Report on MTSR
Metsera Price Performance
The company's 50-day moving average is $23.72.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Metsera
A number of hedge funds have recently added to or reduced their stakes in MTSR. Strs Ohio acquired a new position in Metsera during the 1st quarter worth approximately $76,000. New York State Common Retirement Fund purchased a new stake in Metsera during the 1st quarter valued at approximately $131,000. Corebridge Financial Inc. acquired a new stake in shares of Metsera during the first quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Metsera during the first quarter worth about $248,000. Finally, MetLife Investment Management LLC acquired a new position in Metsera during the 1st quarter worth approximately $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
